

1 **Longitudinal Surveillance for SARS-CoV-2 Among Staff in Six Colorado Long-Term Care**  
2 **Facilities: Epidemiologic, Virologic and Sequence Analysis**

3 Emily N. Gallichotte<sup>1\*</sup>, Kendra M. Quicke<sup>1\*</sup>, Nicole R. Sexton<sup>1</sup>, Emily Fitzmeyer<sup>1</sup>, Michael C.  
4 Young<sup>1</sup>, Ashley J. Janich<sup>1</sup>, Karen Dobos<sup>1</sup>, Kristy L Pabilonia<sup>1</sup>, Gregory Gahm<sup>2,3</sup>, Elizabeth J.  
5 Carlton<sup>4</sup>, Gregory D. Ebel<sup>1</sup>, Nicole Ehrhart<sup>5</sup>

6 <sup>1</sup> Arthropod-Borne and Infectious Diseases Laboratory, Department of Microbiology,  
7 Immunology and Pathology, Colorado State University, Ft. Collins, CO 80526.

8 <sup>2</sup> Department of Geriatric Medicine, University of Colorado Medical Center

9 <sup>3</sup> Vivage Senior Living, Denver, CO 80228

10 <sup>4</sup> Department of Environmental and Occupational Health, Colorado School of Public Health,  
11 University of Colorado, Anschutz, Aurora, CO 80045

12 <sup>5</sup> Columbine Health Systems Center for Healthy Aging and Department of Clinical Sciences,  
13 Colorado State University, Fort Collins, CO 80523

14 \* Co-first authors

15

16 **Addresses for Correspondence:**

17 Gregory D. Ebel, Sc.D.

18 Professor, Department of Microbiology, Immunology and Pathology

19 Director, Arthropod-Borne and Infectious Diseases Laboratories

20 Colorado State University

21 Ft. Collins, CO 80526

22 [gregory.ebel@colostate.edu](mailto:gregory.ebel@colostate.edu)

23

24 Nicole Ehrhart, VMD, MS, Diplomate ACVS

25 Professor, Surgical Oncology, Department of Clinical Sciences

26 School of Biomedical Engineering

27 Flint Animal Cancer Center

28 Colorado State University

29 Ft. Collins, CO 80526

30 [nicole.ehrhart@colostate.edu](mailto:nicole.ehrhart@colostate.edu)

31

32

33

34

35 **Abstract**

36 **Background:** SARS-CoV-2 emerged in 2019 and has become a major global pathogen. Its  
37 emergence is notable due to its impacts on individuals residing within long term care facilities  
38 (LTCFs) such as rehabilitation centers and nursing homes. LTCF residents tend to possess  
39 several risk factors for more severe SARS-CoV-2 outcomes, including advanced age and  
40 multiple comorbidities. Indeed, residents of LTCFs represent approximately 40% of SARS-CoV-  
41 2 deaths in the United States.

42

43 **Methods:** To assess the prevalence and incidence of SARS-CoV-2 among LTCF workers,  
44 determine the extent of asymptomatic SARS-CoV-2 infection, and provide information on the  
45 genomic epidemiology of the virus within these unique care settings, we collected  
46 nasopharyngeal swabs from workers for 8-11 weeks at six Colorado LTCFs, determined the  
47 presence and level of viral RNA and infectious virus within these samples, and sequenced 54  
48 nearly complete genomes.

49

50 **Findings:** Our data reveal a strikingly high degree of asymptomatic/mildly symptomatic  
51 infection, a strong correlation between viral RNA and infectious virus, prolonged infections and  
52 persistent RNA in a subset of individuals, and declining incidence over time.

53

54 **Interpretation:** Our data suggest that asymptomatic SARS-CoV-2 infected individuals  
55 contribute to virus persistence and transmission within the workplace, due to high levels of virus.  
56 Genetic epidemiology revealed that SARS-CoV-2 likely spreads between staff within an LTCF.

57

58 **Funding:** Colorado State University Colleges of Health and Human Sciences, Veterinary  
59 Medicine and Biomedical Sciences, Natural Sciences, and Walter Scott, Jr. College of  
60 Engineering, the Columbine Health Systems Center for Healthy Aging, and the National Institute  
61 of Allergy and Infectious Diseases.

62

63

64

65

66

67

68

69 **Research in Context**

70 **Evidence before this study:** We searched PubMed and Google Scholar on April 15, 2020 for  
71 manuscripts published in 2020 with the key words “SARS-CoV-2 OR COVID-19 AND Long-  
72 Term Care Facility AND Surveillance OR Screening. We did not restrict our search to the  
73 English language. Our search retrieved two reports of original research. The relevant  
74 publications described transmission and course of infection among residents in LTCFs. Of  
75 particular relevance was that large quantities of SARS-CoV-2 viral RNA could be detected in  
76 asymptomatic, presymptomatic and symptomatic residents, providing early evidence of the  
77 heterogeneity of infection characteristics among residents at LTCFs. A significant number of  
78 LTCF residents were presymptomatic with symptoms emerging 7 days after initial detection of  
79 viral RNA, indicating a longer than expected latency period. Therefore, symptomatic screening  
80 for early detection and resultant mitigation response was likely to be ineffective in preventing  
81 transmission among residents of LTCFs. There were no reports involving longitudinal  
82 surveillance testing of LTCF staff.

83  
84 **Added value of this study:** While prior studies reported results of facility-wide (residents and  
85 staff) testing for SARS-CoV-2 and describe transmission dynamics among residents of LTCFs,  
86 no prior data was available describing the longitudinal characteristics of SARS-CoV-2 dynamics  
87 among staff working at LTCFs during a time period where “shelter-in-place” public guidance was  
88 in effect. During this time period, LTCF residents were largely isolated, however staff (those with  
89 both direct care and those without direct contact) were permitted to leave and return to work  
90 daily. We were therefore interested in this broad staff cohort specifically because they represent  
91 a significant and ongoing potential source of transmission within LTCFs. RT-qPCR testing for  
92 SARS-CoV-2 was performed weekly on 544 staff in six LTCFs over an 8-11-week period.  
93 Symptom data were collected and site-specific prevalence at study onset and incidence rate  
94 over time were calculated to explore the influence of identifying and removing asymptomatic  
95 SARS-CoV-2-infected individuals from the workplace.

96  
97 **Implications of all the available evidence:** Our results document a surprising degree of  
98 asymptomatic/mildly symptomatic infection among apparently healthy staff, and extreme  
99 variation in SARS-CoV-2 prevalence and incidence among staff between different facilities.  
100 Plaque assay revealed a strong relationship between vRNA and infectious virus in  
101 nasopharyngeal swab material, indicating the asymptomatic or mildly symptomatic individuals  
102 are infectious. Moreover, phylogenetic analysis of SARS-CoV-2 sequences collected from LTCF

103 staff suggest that the predominant transmission pattern is between staff members within  
104 facilities, and that individual unrelated community import events are less common. Finally,  
105 decreasing prevalence over time within facilities where longitudinal surveillance testing was  
106 performed suggests that identifying and isolating positive staff may serve as part of an effective  
107 mitigation program to prevent or curtail transmission among staff within LTCFs.

108

109

## 110 **Introduction**

111 The highly infectious SARS-CoV-2 virus threatens the stability of healthcare systems around the  
112 world. Long term care facilities (LTCFs), due to their communal nature, the limited mobility of  
113 their inhabitants and the propensity of residents to have underlying health conditions, have  
114 become significant venues of virus transmission [1]. The COVID-19 pandemic has resulted in  
115 disproportionately high morbidity and mortality among residents in LTCFs. As of October 10,  
116 2020, the Centers for Medicare and Medicaid Services reported over 84,000 deaths due to  
117 COVID-19 in U.S. LTCFs, representing over 38% of COVID-19-related deaths [2, 3]. In the U.S.,  
118 the first recorded SARS-CoV-2 outbreak occurred in a LTCF in Washington as early as  
119 February [4]. Since then, every state has recorded outbreaks in LTCFs, and in 14 states LTCF  
120 deaths account for over 50% of all COVID-19 deaths [3]. The high mortality associated with  
121 SARS-CoV-2 infection within LTCFs is principally due to the risk profiles of residents residing in  
122 communal care settings, including advanced age and pre-existing comorbidities, such as heart  
123 disease and diabetes mellitus [5-7].

124

125 Accordingly, strategies to mitigate SARS-CoV-2 transmission to LTCF residents have included  
126 restricting visitation, cessation of group activities and dining, and confinement to individual living  
127 quarters [8-11]. While LTCF residents have been largely isolated from external visitation, staff  
128 are permitted contact provided they have passed a daily screening process to assess for fever,  
129 COVID-19 respiratory symptoms or known exposure [12]. These staff have the potential to  
130 import the virus into facilities, resulting in spread to residents, other workers, and back to the  
131 outside community [1]. While symptom screening can reduce virus spread, a significant fraction  
132 of individuals infected with SARS-CoV-2 have a lengthy latency period prior to exhibiting  
133 COVID-19 symptoms, and many remain asymptomatic throughout the course of infection [13-  
134 18]. Therefore, pre-symptomatic, asymptomatic and mildly symptomatic LTCF staff are a  
135 potential source of transmission within LTCFs and are thus an attractive focus for interventions  
136 directed at suppressing infections within these facilities [15, 16, 19-23].

137

138 While there are a growing number of studies measuring SARS-CoV-2 infection within LTCF  
139 residents, there are limited studies focusing on longitudinal surveillance of LTCF asymptomatic  
140 staff [24]. In Colorado, cases linked to LTCFs account for over 49% of all COVID-19 deaths [2,  
141 3]. To evaluate the impact of staff on virus introduction into LTCFs, we tested staff at six  
142 Colorado LTCFs for SARS-CoV-2. Staff were enrolled and sampled by nasopharyngeal swab  
143 weekly for 8-11 consecutive weeks. Samples were assayed for virus by RT-qPCR and plaque  
144 assay, and individuals with evidence of infection were instructed to self-quarantine for ten days.  
145 Return to work required absence of fever for the final three days of isolation. Using data on staff  
146 infection, site-specific prevalence at study onset and incidence rate over time were calculated.  
147 Viral genomes were sequenced to assess viral genetic diversity within and between LTCFs.

148

149 Our results document a surprising degree of asymptomatic/mildly symptomatic infection among  
150 apparently healthy staff, and extreme variation in SARS-CoV-2 prevalence and incidence  
151 between different facilities, similar to what has been observed at other LTCFs [15, 16, 19, 22].  
152 We documented a range of infection courses, including acute (1 week), prolonged (4+ weeks),  
153 and recrudescent. Sequencing studies lend support to the observation that transmission may  
154 occur within LTCFs and, combined with the epidemiologic and other data provided here,  
155 highlight the importance of testing and removing virus-positive workers in order to protect  
156 vulnerable LTCF residents. Data obtained from longitudinal surveillance studies provide crucial  
157 information about infectious disease transmission dynamics within complex workforces and  
158 inform best practices for preventing or mitigating COVID-19 outbreaks within LTCFs.

159

## 160 **Materials and Methods.**

161 **Study sites.** Staff at LTCFs provided consent to participate in this study. Nasopharyngeal (NP)  
162 swabs, or saliva (only sampled once at two facilities when swabs were unavailable) were  
163 collected weekly for 8-11 weeks. Participants provided date of birth and job code but were  
164 otherwise de-identified. This study was reviewed and approved by the Colorado State University  
165 IRB under protocol number 20-10057H. Participants were promptly informed of test results and  
166 when positive, instructed to self-isolate for ten days. Return to work required absence of fever or  
167 other symptoms for the final three days of isolation.

168

169 **Sample collection.** Nasopharyngeal swabs were collected by trained personnel. Swabs were  
170 placed in a conical tube containing 3ml viral transport media (Hanks Balanced Salt Solution, 2%

171 FBS, 50mg/ml gentamicin, 250ug/ml amphotericin B/fungizone). Saliva was collected by  
172 repeatedly spitting through a straw into a sterile tube.

173  
174 **RNA extraction.** Tubes containing NP swabs were vortexed and centrifuged to pellet debris.  
175 RNA was extracted from supernatant with the Omega Mag-Bind Viral DNA/RNA 96 Kit using  
176 200ul of input sample on a KingFisher Flex magnetic particle processor according to the  
177 manufacturers' instructions.

178  
179 **qRT-PCR.** One-step reverse transcription and PCR was performed using the EXPRESS One-  
180 Step SuperScript qRT-PCR Kit (ThermoFisher Scientific) per the manufacturers' instructions.  
181 N1, N2, and E primer/probes were obtained from IDT and described elsewhere [25-27]. RNA  
182 standards for nucleocapsid (N) and envelope (E) were provided by Dr. Nathan Grubaugh of  
183 Yale University and used to determine copy number [26]. Samples were screened with N1  
184 primer/probes, and those with a cycle threshold (CT) less than 38 were tested for N2 and E  
185 vRNA.

186  
187 **Plaque assay.** Plaque assays were performed on African Green Monkey Kidney (Vero) cells  
188 (ATCC CCL-81) according to standard methods [28]. Briefly, 250uL of serially diluted samples  
189 were inoculated onto cell monolayer for one hour. After incubation, cells were overlaid with  
190 tragacanth medium, incubated for two days, fixed and stained with 30% ethanol and 0.1%  
191 crystal violet. Plaques were counted manually.

192  
193 **Incidence estimation.** The rate at which staff acquired infections was estimated as the number  
194 of new infections per 100 workers per week at each facility from week 2 through the end of the  
195 study. Staff were classified as having an incident infection if they tested positive for the first time  
196 following a negative test one- or two-weeks prior and if they had not previously tested positive  
197 for SARS-CoV-2 in our study. The population at risk included all staff who had not yet been  
198 infected, to our knowledge, and who tested negative in week one of the study.

199  
200 **Symptom reporting.** Symptom data were collected and managed with REDCap electronic data  
201 capture tools hosted at the Colorado Clinical and Translational Sciences Institute (CCTSI) at  
202 University of Colorado Anschutz Medical Campus [29, 30]. Survey administrators accessed the  
203 survey on a portable tablet computer, entered a participant-specific case number, and provided  
204 a verbal introduction. Participants were asked to enter responses to questions concerning

205 symptoms, symptom severity, comorbidities, household size, general characteristics (height,  
206 weight, etc.), smoking habits, inhaled medication use, and potential exposure to SARS-CoV-2.  
207 Symptom severity and exposure questions were phrased to encompass a range of time from  
208 mid-March to late-June. Survey participants were asked to recall symptoms coinciding with this  
209 time period.

210  
211 **Next-generation sequencing and analysis.** cDNA was generated using SuperScript IV  
212 Reverse Transcriptase enzyme (Invitrogen) with random hexamers. PCR amplification was  
213 performed using ARTIC network V2 or V3 tiled amplicon primers in two separate reactions by  
214 Q5 High-Fidelity polymerase (NEB) as previously described [31]. First-round PCR products  
215 were purified using Ampure XP beads (Beckman Coulter). Libraries were prepared using the  
216 Nextera XT Library Preparation Kit (Illumina) according to manufacturer protocol. Unique  
217 Nextera XT i7 and i5 indexes for each sample were incorporated for dual indexed libraries.  
218 Indexed libraries were again purified using Ampure XP beads. Final libraries were pooled and  
219 analyzed for size distribution using the Agilent High Sensitivity D1000 Screen Tape on the  
220 Agilent TapeStation 2200. Final quantification was performed using the NEBNext Library Quant  
221 Kit for Illumina (NEB) according to manufacturer protocol. Libraries were sequenced on the  
222 Illumina MiSeq V2 using 2 x 250 paired-end reads.

223  
224 Sequencing data were processed to generate consensus sequences for each viral sample.  
225 MiSeq reads were demultiplexed, quality checked by FASTQC, paired-end reads were  
226 processed to remove Illumina primers and quality trimmed with Cutadapt; duplicate reads were  
227 removed. Remaining reads were aligned to SARS-CoV-2 WA1-F6/2020 reference sequence by  
228 Bowtie2 (GenBank: MT020881.1). Alignments were further processed, quality checked using  
229 Geneious software, consensus sequences were determined, and any gaps in sequences were  
230 filled in with the reference sequence or cohort specific consensus sequence. Consensus  
231 sequences were aligned in Geneious and a maximum-likelihood tree generated using PhyML in  
232 Geneious with the Wuhan-Hu-1 reference sequence (GeneBank: MN908947.3) as an outgroup  
233 and 100 bootstrap replicates.

234

## 235 **Results**

236

237 **Cohort characteristics.** From March 26 to June 23, 2020, we tested 544 staff from six LTCFs  
238 (**Table 1**). Of these participants, 91 (16.7%) tested positive for SARS-CoV-2 viral RNA (vRNA)

239 at least once during the study. We tested 3, 754 samples total, of which 179 were positive for  
240 vRNA (4.77% of total samples).

241  
242 **Viral load, prevalence and incidence rate vary across LTCFs.** Viral RNA levels and the  
243 prevalence of vRNA-positive swabs varied each week by site (**Fig. 1A & B**). Staff at Site A  
244 remained uninfected throughout the entire 8-week study period, whereas 31% of individuals at  
245 site D were infected on week two. All sites showed a decline in SARS-CoV-2 prevalence over  
246 the course of the study (**Fig. 1B**). SARS-CoV-2 incidence also varied across sites (**Fig. 1C**). At  
247 site D, which had the highest SARS-CoV-2 prevalence, the initial incidence was also high (13.6  
248 cases per 100 person-weeks) but declined over time. At sites C and F, the incidence reached  
249 zero by week 3, however both sites had a small number of incident cases in later weeks. Sites B  
250 and E, which had low prevalence in week 1, saw an increase in cases. At site B, incident  
251 infections were detected after three weeks. Infections were observed in all job classes, including  
252 those with typically high patient contact (e.g. nursing) and low patient contact (e.g.  
253 maintenance) (**Table 2**). The highest odds ratios for infection occurred in housekeeping, nursing  
254 and staff in other jobs, while the lowest were in administration, therapy and dietary staff (**Table**  
255 **2**).

256  
257 **Relationship between viral RNAs and infectious virus in nasopharyngeal swabs.** Swabs  
258 with SARS-CoV-2 N1 vRNA were tested for N2- and E-containing viral transcripts (**Fig. 2A**). We  
259 observed high concordance between levels of N1 and N2 vRNA, with a median genome to  
260 genome ratio of 1.2 (**Fig. 2B**). E vRNA levels were lower and less detectable than either N1 or  
261 N2 (**Fig. 2A**), consistent with coronavirus replication, resulting in higher genome ratios (**Fig.**  
262 **2B**). Samples with detectable N1 vRNA were also tested for infectious virus. We found a strong  
263 positive relationship between vRNA and infectious virus in swab material (**Fig. 2C**). Infectious  
264 virus was rarely detected in individuals with fewer than  $10^5$  N1 vRNA copies. However, there  
265 were some samples with high levels of vRNA ( $\sim 10^7$  copies) with undetectable infectious virus.  
266 Virus specific infectivity varied depending on the region of the genome analyzed (**Fig. 2D**).

267  
268 **SARS-CoV-2 infection and vRNA levels are not related to age, BMI, sex or job code.** Age,  
269 body mass index (BMI), sex and smoking habits have been implicated in SARS-CoV-2 infection  
270 and disease outcomes [32-38]. We detected no significant differences between these variables  
271 among vRNA-negative and vRNA-positive individuals (**Table 3**). Viral RNA level from N1-  
272 positive samples was not dependent on age, BMI, sex, smoking habits or job code (**SFig. 1**).



273

274 **Symptom status differs based on SARS-CoV-2 infection status.** A subset of study  
275 participants ( $n = 191$  vRNA-,  $n = 51$  vRNA+), responded to a survey to capture recollection of  
276 eleven COVID-19-related symptoms during the study period [39] (**Table 4**). All symptoms were  
277 significantly more frequent among infected participants. Cough and fever  $>100.4^{\circ}\text{F}$ , two  
278 symptoms commonly used for COVID screening, were reported in 48% and 24% of infected  
279 participants, as compared to 14.3% and 7.4% in uninfected individuals. Other symptoms such  
280 as the loss of taste and smell (ageusia and anosmia), were significantly associated with SARS-  
281 CoV-2 infection (reported in 2.1% of vRNA-negative and 51.0% of vRNA-positive individuals).

282

283 **Symptom status and severity is related to SARS-CoV-2 infection.** vRNA-positive individuals  
284 recalled more symptoms than vRNA-negative individuals ( $p < 0.001$ ) (**Fig. 3A**). Almost 80% of  
285 vRNA-negative individuals experience 0-1 symptoms, whereas vRNA-positive individuals evenly  
286 recalled a range of symptoms (**Fig. 3B**). 27% of vRNA-positive individuals reported zero  
287 symptoms, and 41% reported 2 or fewer symptoms (**Fig. 3C**). Severity was scored (0-no  
288 symptom, 1-mild, 2-moderate, 3-severe) for each symptom, and symptom score was compared  
289 between vRNA-negative and positive individuals. Average symptom score was significantly  
290 higher in vRNA-positive individuals ( $p < 0.001$ ) (**Fig. 3D**). Over 70% of vRNA-negative individuals  
291 had a symptom severity score of 1 or less, whereas vRNA-positive individuals had an evenly  
292 broad range of scores (**Fig. 3E**). Within vRNA-positive individuals, total symptom score was not  
293 correlated with N1 vRNA levels (**Fig. 3F**). N1 vRNA levels were stratified by severity for each  
294 symptom. N1 vRNA did not predict the severity of any symptom independently (**S2Fig**).

295

296 **Participants experienced acute, prolonged and resurgent SARS-CoV-2 infections.** Within  
297 the cohort and study period, we observed a range of infection courses (**Fig. 4A-E**). Individuals  
298 who were positive for a single week included those with low levels of vRNA and no detectable  
299 infectious virus (B150), to those with high levels of both vRNA and infectious virus (F058) (**Fig.**  
300 **4A**). Individuals who were positive for multiple consecutive weeks often had high levels of virus  
301 on their first positive test which decreased in subsequent weeks (**Fig. 4B-D**). There were also  
302 individuals with positive SARS-CoV-2 tests followed by 1-3 weeks of negative tests, before  
303 vRNA was again detected (**Fig. 4E**). Individuals with incident infections during the course of the  
304 study, with negative tests before and after positives, were stratified based on the number of  
305 consecutive vRNA-positive weeks (**Fig. 4F**). Those who were vRNA-positive for a single week  
306 tended to have low N1 levels and rarely had infectious virus (**Fig. 4F**). Virus levels in infections

307 that lasted 2-4 weeks, were generally highest on the first week and subsequently decreased  
308 (**Fig. 4F**). Individuals with post-negative positive tests (positive after 1-3 weeks of negative tests  
309 following initial infection), were associated with very low levels of vRNA and rarely infectious  
310 virus (**Fig. 4F**).

311  
312 **Phylogenetic analysis of SARS-CoV-2 sequences from LTCFs.** 54 partial genome  
313 sequences were obtained from individuals with infections during the study (**Fig. 5**). Mean  
314 genome coverage was 29,317nt (range = 24,076-29,835) and mean coverage depth was 640  
315 reads per position (range = 344-2,138). Gaps in sequencing alignment due to ARTIC V2/V3  
316 primer incompatibilities were filled in with the reference strain MT020881.1. The LTCF  
317 sequences were aligned to a reference strain from early in the U.S. outbreak (WA1-F6), four  
318 Colorado strains (CO-CDC), and strains from California (USA-CA1), New York (USA/NY) and  
319 Wuhan (Wuhan-Hu-1). The tree was reasonably resolved into multiple clusters with moderate  
320 bootstrap support (i.e. >50%). The largest cluster is composed exclusively of sequences  
321 obtained from individuals at site D (**Fig. 5**, lower part of tree). Sequences from sites C (red) and  
322 E (orange) primarily cluster amongst themselves, however there are site C sequences within the  
323 D clusters as well. The single sequence from site B (B137\_05/08/20), is most similar to site C  
324 sequences.

## 325 326 **Discussion**

327 LTCFs are increasingly recognized as high-risk for SARS-CoV-2 transmission [12, 19, 23].  
328 Because of their disproportionate contribution to the burden of COVID-19 mortality [2, 3], they  
329 also represent an attractive target for surveillance testing [11]. Consistent with other LTCF  
330 cohorts [15, 16, 20], our data clearly demonstrate the potential for large numbers of staff at  
331 LTCFs to be asymptotically/presymptomatically infected and for the concentration of infection  
332 to vary widely across facilities. One facility had no positive staff, while others had up to 30% of  
333 staff test positive within the same sampling period. The steady decline in new infections in  
334 facilities with the highest initial infection prevalence following removal of SARS-CoV-2-positive  
335 staff from the workplace is encouraging and hints at the potential impact of longitudinal  
336 surveillance. The detection of incident infections at facility B, after three weeks of negative tests  
337 underscores the on-going threat of infections in worker populations. These results clearly  
338 demonstrate that infected staff may be common in specific LTCFs [15-17, 19].

339

340 Because coronavirus genome replication creates an abundance of sub-genomic N-containing  
341 transcripts [40], it is therefore not surprising that higher levels of N transcripts are detected  
342 compared to E vRNA. We found that viral RNA was strongly correlated with infectious virus  
343 (samples with high levels of vRNA tended to have high levels of infectious virus, whereas lower  
344 vRNA levels often had undetectable levels of infectious virus). Importantly, this demonstrates  
345 that individuals with high levels of vRNA are likely infectious to others [41-43]. We also detected  
346 infectious virus in asymptomatic individuals, and at time points later than other reports,  
347 suggesting that presence and duration of infectious virus varies greatly by individual [44].  
348 Our data supports the observation that seemingly healthy staff can harbor high levels of  
349 infectious virus in the absence of clinical disease and may therefore contribute to transmission  
350 of SARS-CoV-2.

351  
352 The impact of age, sex, BMI, race, ethnicity, and other patient characteristics on SARS-CoV-2  
353 infection and disease outcomes are not well defined [32-37]. Within our cohort, we detected no  
354 relationship between any of these factors and RNA load, symptom number or severity.  
355 Additionally, while symptom status and severity are strongly correlated to positive SARS-CoV-2  
356 results, viral load is not correlated with either status or severity. Notably, others have found that  
357 symptomatic hospitalized patients have lower virus levels than non-hospitalized peers [45].  
358 Together, these results suggest that other host or viral factors likely impact virus level and  
359 clinical presentation.

360  
361 The longitudinal design of this study permitted characterization of individuals' full infection  
362 courses, including those who were positive for 1-5 consecutive weeks. In most cases, viral load  
363 was highest in the first week, then declined. Consistent with other reports [46-49], we observed  
364 individuals with positive tests after apparent clearance of the initial infection. While it is possible  
365 that these individuals were re-infected immediately after clearing their initial infection, we find  
366 that unlikely [50, 51]. Instead, this may be due to host factors that lead to temporary  
367 suppression of virus within the nasopharynx, or an improper swab collection that failed to  
368 capture sufficient material for detection [52]. Importantly, the post-negative positive samples  
369 contained low levels of vRNA, and low or undetectable infectious virus. These data highlight the  
370 heterogeneity of human SARS-CoV-2 infection, and the need to further understand host and  
371 viral factors that govern infection and clearance.

372

373 Virus sequencing provides insights into SARS-CoV-2 transmission [24]. Our data encompasses  
374 54 genomes obtained from four sites. Strikingly, the viruses primarily cluster by facility,  
375 suggesting local transmission among staff at each site. It is possible there are also community-  
376 acquired infections which are introduced to the facilities, which could explain highly similar virus  
377 sequences at multiple sites. Data on the degree of viral genetic diversity in the larger community  
378 would add significant power to our ability to discriminate between these two non-mutually  
379 exclusive scenarios. Additional comparisons to existing SARS-CoV-2 sequences would also  
380 help elucidate introduction and spread within the facilities and Colorado as a whole [31].

381  
382 Overall, our study highlights the high SARS-CoV-2 infection rates within staff at LTCFs.  
383 Identifying and isolating these infected and infectious individuals, may serve as an effective  
384 mitigation strategy. While our work focused on LTCFs, this approach could be applied to other  
385 communal living settings (correctional facilities, factories, etc.).

### 386 **Acknowledgements**

388 This work was supported by funds donated by the Colorado State University Colleges of Health  
389 and Human Sciences, Veterinary Medicine and Biomedical Sciences, Natural Sciences, and  
390 Walter Scott, Jr. College of Engineering, and the Colorado State University Columbine Health  
391 Systems Center for Healthy Aging. KMQ was supported by a fellowship from the National  
392 Institute of Allergy and Infectious Diseases, National Institutes of Health under grant number  
393 F32AI150123-01. The authors also gratefully acknowledge the CSU Veterinary Diagnostic  
394 Laboratory for diagnostic support, Carolina Mehaffy for courier support, and the participation of  
395 the workers in the facilities that participated in this study, without which it could not have been  
396 completed. The funding sources had no role in the writing of this manuscript or the decision to  
397 submit it for publication. None of the authors have been paid to write this publication. The  
398 authors declare no conflicts of interest.

### 399 **Legends**

400 **Table 1. Colorado LTCF cohort characteristics.**

		<b>All participants (n = 544) n (%)</b>	<b>vRNA+ participants (n = 91) n (%)</b>
Site	A	100 (18%)	0 (0%)
	B	108 (20%)	8 (9%)
	C	51 (9%)	10 (11%)
	D	128 (24%)	54 (59%)
	E	76 (14%)	14 (15%)

F	81 (15%)	5 (5%)
Total NP swabs tested	3591	179
Total saliva tested	163	0

402  
403 **Table 2. Analysis of infections in LTCF staff by job code.** The distribution of infections by job  
404 code among 435 staff at LTCFs where SARS-CoV-2 was detected during the study period.

Job code	Number tested	% positive*	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Administration	53	11.3	1.00 (ref)	1.00 (ref)
Nursing	180	24.4	2.53 (1.01, 6.33)	2.79 (1.07, 7.32)
Housekeeping	96	14.6	1.34 (0.48, 3.71)	4.69 (1.39, 15.84)
Dietary	36	19.4	1.89 (0.58, 6.18)	1.55 (0.45, 5.34)
Therapy	24	4.2	0.34 (0.04, 3.00)	0.47 (0.05, 4.45)
Other**	46	34.8	4.18 (1.47, 11.87)	4.91 (1.61, 14.97)

405 \*Analysis looks at the percent of workers that tested positive at least once during the study period.  
406 Analysis is limited to the five sites where SARS-CoV-2 was detected (B, C, D, E, F). Unadjusted odds  
407 ratios were estimated using logistic regression, adjusted analyses included a dummy variable for site.  
408 \*\*Other jobs include physician/provider, maintenance, social services, transport, and activities.

409  
410 **Table 3. Age, BMI and smoking status among cohort subset.**

	vRNA-	vRNA+	p-value
Age, mean (range)	41 (17-76) (n = 454)	41 (16-72) (n = 91)	0.7645 <sup>†</sup>
BMI, mean (range)	28.7 (17.8-46.6) (n = 190)	28.2 (20.8-43.0) (n = 51)	0.3265 <sup>†</sup>
Current smokers	21.2% (40/190)	16.3% (8/49)	0.5516 <sup>‡</sup>
Former smokers*	20.0% (28/190)	24.5% (12/49)	0.1315 <sup>‡</sup>
Marijuana smokers	5.3% (10/188)	6.1% (3/49)	0.7348 <sup>‡</sup>
Tobacco-based vape product users	6.3% (12/189)	4.2% (2/48)	0.7412 <sup>‡</sup>

411 \*Former smoker refers to those who answered 'Yes' to 'are you a former smoker' and 'No' to 'Do you  
412 currently smoke cigarettes'.  
413 <sup>†</sup>T-test, <sup>‡</sup>Fisher's Exact Test

414  
415 **Table 4. Symptom status among vRNA-negative and positive individuals.**

Symptom	Percent reporting among:		
	vRNA-	vRNA+	p-value
Cough	14.3%	48.0%	<0.001
Dyspnea	8.9%	41.2%	<0.001
Fever >100.4°F	7.4%	24.0%	0.0035
Chills / Shaking	5.9%	40.0%	<0.001
Muscle Pain	10.6%	54.9%	<0.001
Headache	22.8%	60.8%	<0.001
Sore Throat	10.7%	43.1%	<0.001
Ageusia / Anosmia	2.1%	51.0%	<0.001
Diarrhea	5.9%	36.0%	<0.001
Nasal Congestion	16.4%	42.0%	<0.001

Nausea / Vomiting | 7.7% 25.0% 0.002

416

417 **Figure 1. SARS-CoV-2 infection in six Colorado LTCFs. A)** SARS-CoV-2 N1 vRNA levels in  
418 nasopharyngeal swabs (circle) or saliva (triangle). Y-axis represents N1 copies/swab or saliva.  
419 Dotted line indicates limit of detection. Numbers across the top indicate number of samples  
420 tested each week. **B)** Prevalence of SARS-CoV-2 each week at each site (percent of samples  
421 with detectable N1 vRNA out of total number tested). **C)** Incident cases were defined as  
422 individuals who tested positive for N1 vRNA for the first time and had tested negative for  
423 infection one or two weeks prior. Not shown are prevalent infections among workers tested for  
424 the first time in week two.

425

426 **Figure 2. Relationship between SARS-CoV-2 viral RNA and infectious virus.** Samples with  
427 detectable SARS-CoV-2 N1 vRNA were evaluated for N2 and E vRNA and infectious virus. **A)**  
428 Relationship between levels of N1, N2 and E vRNA transcripts. **B)** Genome:genome ratios  
429 between N1:N2, N1:E and N2:E (median with interquartile range). **C)** Relationship between  
430 levels of infectious virus and N1, N2, and E vRNA levels. **D)** Specific infectivity (genome:PFU  
431 ratio) of infectious virus relative to N1, N2 and E transcripts (median with interquartile range).  
432 Dashed lines represent limits of detection. PFU, plaque forming units.

433

434 **Figure 3. SARS-CoV-2 symptom status, severity and relationship to viral RNA. A)** Number  
435 of symptoms reported by vRNA- and vRNA+ participants (mean  $\pm$  SD). **B)** Percentage of vRNA-  
436 and vRNA+ individuals stratified by number of symptoms. **C)** Percentage of vRNA+ survey  
437 participants reporting total number of symptoms. **D)** Cumulative symptom score (not reported =  
438 0, mild = 1, medium = 2, severe = 3) for all 11 symptoms stratified by vRNA- and vRNA+  
439 participants (mean  $\pm$  SD). **E)** Percentage of vRNA- and vRNA+ individuals stratified by symptom  
440 score. **F)** Relationship between cumulative symptom score and N1 vRNA levels (semilog  
441 nonlinear regression line fit). \*\*\*  $p < 0.0001$  Mann-Whitney unpaired non-parametric test.

442

443 **Figure 4. Individual infection courses and virus levels.** Viral N1 RNA (left axis) and  
444 infectious virus (right axis) in select individuals with detectable N1 for **A)** one, **B)** two, **C)** three,  
445 or **D)** four consecutive weeks. **E)** Examples of individuals with detection of N1 vRNA after a  
446 period of undetectable N1 following initial infection. **F)** N1 vRNA and infectious virus by week of  
447 infection is plotted for individuals with incident infectious during the course of the study, with  
448 negative (N) tests immediately before and after positive (P) tests, stratified by the length of

449 infection (one, two, three or four consecutive positive weeks) and those who experienced a  
450 post-negative positive test (following 1-3 negative weeks). Dashed line represents limit of  
451 detection, samples not detected plotted at half the limit of detection. PFU, plaque forming units.

452

453 **Figure 5. Phylogenetic analysis of SARS-CoV-2 genomes collected from Colorado**  
454 **LTCFs. A)** PhyML tree constructed using Tamura-Nei distance model including both transitions  
455 and transversions in Geneious Prime. Node numbers indicate bootstrap confidence based on  
456 1000 replicates. Distance matrix was computed, and the tree was visualized in Geneious Prime.  
457 Letters at the beginning of taxon names represent job code (AC-activities, AD-administrative,  
458 AM-admissions, DT-dietary, MT-maintenance, NS-nursing, SS-social services, UK-unknown),  
459 and A-E letter indicate site of origin. Numbers after underscore indicate the date of sample  
460 collection. Reference sequences and four Colorado-derived sequences were obtained from  
461 NCBI. **B)** Map of the LTCFs' relative geographic locations and distances from one another.

462

#### 463 **Supplemental Legends**

464 **Supplemental Figure 1. Virus levels stratified by participant age, body mass index, sex,**  
465 **and job code.** Participants were stratified by **A)** age (n = 91), **B)** BMI (n = 51), **C)** sex (n = 79),  
466 **D)** smoking habits, and **E)** job code (n = 90). N1 vRNA from all N1-positive samples were  
467 plotted. **A and B)** Semilog nonlinear regression line fit, and **C-D)** bar and errors represent  
468 median with interquartile range. Dashed line represents limit of detection.

469

470 **Supplemental Figure 2. N1 vRNA and symptom severity.** N1vRNA levels for each symptom  
471 stratified by symptom severity. Bar and errors represent median with interquartile range.  
472 Dashed line represents limit of detection.

473

#### 474 **References:**

- 475 1. CDC. *Preparing for COVID-19 in Nursing Homes*. 2020; Available from:  
476 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html>.
- 477 2. *The Nursing Home COVID-19 Public File*. 2020; Available from:  
478 <https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/>.
- 479 3. *More Than 40% of U.S. Coronavirus Deaths Are Linked to Nursing Homes*. 2020;  
480 Available from: [https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-](https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html)  
481 [homes.html](https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html).
- 482 4. McMichael, T.M., et al., *COVID-19 in a Long-Term Care Facility - King County,*  
483 *Washington, February 27-March 9, 2020*. MMWR Morb Mortal Wkly Rep, 2020.  
484 **69**(12): p. 339-342.

- 485 5. Gorges, R.J., P. Sanghavi, and R.T. Konetzka, *A National Examination Of Long-Term*  
486 *Care Setting, Outcomes, And Disparities Among Elderly Dual Eligibles*. Health Aff  
487 (Millwood), 2019. **38**(7): p. 1110-1118.
- 488 6. Wang, L., et al., *Coronavirus disease 2019 in elderly patients: Characteristics and*  
489 *prognostic factors based on 4-week follow-up*. J Infect, 2020. **80**(6): p. 639-645.
- 490 7. Jutzeler, C.R., et al., *Comorbidities, clinical signs and symptoms, laboratory findings,*  
491 *imaging features, treatment strategies, and outcomes in adult and pediatric patients with*  
492 *COVID-19: A systematic review and meta-analysis*. Travel Med Infect Dis, 2020: p.  
493 101825.
- 494 8. Laxton, C.E., et al., *Solving the COVID-19 Crisis in Post-Acute and Long-Term Care*. J  
495 Am Med Dir Assoc, 2020. **21**(7): p. 885-887.
- 496 9. CDC. *Discontinuation of transmission-based precautions and disposition of patients with*  
497 *COVID-19 in healthcare settings (interim guidance)*. 2020; Available from:  
498 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html>.
- 499 10. CDC. *Responding to coronavirus (COVID-19) in nursing*. 2020; Available from:  
500 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-responding.html>.
- 501 11. CDC. *Testing guidance for nursing homes*. 2020; Available from:  
502 <https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homes-testing.html>.
- 503 12. Lester, P.E., et al., *Policy Recommendations Regarding Skilled Nursing Facility*  
504 *Management of Coronavirus 19 (COVID-19): Lessons from New York State*. J Am Med  
505 Dir Assoc, 2020. **21**(7): p. 888-892.
- 506 13. Wu, Z. and J.M. McGoogan, *Asymptomatic and Pre-Symptomatic COVID-19 in China*.  
507 Infect Dis Poverty, 2020. **9**(1): p. 72.
- 508 14. Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19*. JAMA,  
509 2020.
- 510 15. Goldberg, S.A., et al., *Asymptomatic Spread of COVID-19 in 97 Patients at a Skilled*  
511 *Nursing Facility*. J Am Med Dir Assoc, 2020. **21**(7): p. 980-981.
- 512 16. Patel, M.C., et al., *Asymptomatic SARS-CoV-2 infection and COVID-19 mortality during*  
513 *an outbreak investigation in a skilled nursing facility*. Clin Infect Dis, 2020.
- 514 17. Arons, M.M., et al., *Presymptomatic SARS-CoV-2 Infections and Transmission in a*  
515 *Skilled Nursing Facility*. N Engl J Med, 2020. **382**(22): p. 2081-2090.
- 516 18. Oran, D.P. and E.J. Topol, *Prevalence of Asymptomatic SARS-CoV-2 Infection : A*  
517 *Narrative Review*. Ann Intern Med, 2020. **173**(5): p. 362-367.
- 518 19. Kimball, A., et al., *Asymptomatic and Presymptomatic SARS-CoV-2 Infections in*  
519 *Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington,*  
520 *March 2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(13): p. 377-381.
- 521 20. White, E.M., et al., *Variation in SARS-CoV-2 Prevalence in US Skilled Nursing*  
522 *Facilities*. J Am Geriatr Soc, 2020.
- 523 21. Louie, J.K., et al., *Lessons from Mass-Testing for COVID-19 in Long Term Care*  
524 *Facilities for the Elderly in San Francisco*. Clin Infect Dis, 2020.
- 525 22. Sanchez, G.V., et al., *Initial and Repeated Point Prevalence Surveys to Inform SARS-*  
526 *CoV-2 Infection Prevention in 26 Skilled Nursing Facilities - Detroit, Michigan, March-*  
527 *May 2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(27): p. 882-886.
- 528 23. Dora, A.V., et al., *Universal and Serial Laboratory Testing for SARS-CoV-2 at a Long-*  
529 *Term Care Skilled Nursing Facility for Veterans - Los Angeles, California, 2020*.  
530 MMWR Morb Mortal Wkly Rep, 2020. **69**(21): p. 651-655.




- 531 24. Taylor, J., et al., *Serial Testing for SARS-CoV-2 and Virus Whole Genome Sequencing*  
532 *Inform Infection Risk at Two Skilled Nursing Facilities with COVID-19 Outbreaks -*  
533 *Minnesota, April-June 2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(37): p. 1288-  
534 1295.
- 535 25. CDC. *Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR*  
536 *Primers and Probes*. 2020; Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)  
537 [ncov/lab/rt-pcr-panel-primer-probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html).
- 538 26. Vogels, C.B.F., et al., *Analytical sensitivity and efficiency comparisons of SARS-CoV-2*  
539 *RT-qPCR primer-probe sets*. Nat Microbiol, 2020.
- 540 27. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-*  
541 *PCR*. Euro Surveill, 2020. **25**(3).
- 542 28. Weger-Lucarelli, J., et al., *Development and Characterization of Recombinant Virus*  
543 *Generated from a New World Zika Virus Infectious Clone*. J Virol, 2017. **91**(1).
- 544 29. Harris, P.A., et al., *The REDCap consortium: Building an international community of*  
545 *software platform partners*. J Biomed Inform, 2019. **95**: p. 103208.
- 546 30. Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven*  
547 *methodology and workflow process for providing translational research informatics*  
548 *support*. J Biomed Inform, 2009. **42**(2): p. 377-81.
- 549 31. Fauver, J.R., et al., *Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in*  
550 *the United States*. Cell, 2020. **181**(5): p. 990-996 e5.
- 551 32. Gebhard, C., et al., *Impact of sex and gender on COVID-19 outcomes in Europe*. Biol  
552 Sex Differ, 2020. **11**(1): p. 29.
- 553 33. Li, Q., et al., *Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-*  
554 *Infected Pneumonia*. N Engl J Med, 2020. **382**(13): p. 1199-1207.
- 555 34. Meng, Y., et al., *Sex-specific clinical characteristics and prognosis of coronavirus*  
556 *disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients*. PLoS  
557 Pathog, 2020. **16**(4): p. e1008520.
- 558 35. Takahashi, T., et al., *Sex differences in immune responses that underlie COVID-19*  
559 *disease outcomes*. Nature, 2020.
- 560 36. Yang, X., et al., *Clinical course and outcomes of critically ill patients with SARS-CoV-2*  
561 *pneumonia in Wuhan, China: a single-centered, retrospective, observational study*.  
562 Lancet Respir Med, 2020. **8**(5): p. 475-481.
- 563 37. Jones, T.C., et al., *An analysis of SARS-CoV-2 viral load by patient age*. medRxiv, 2020:  
564 p. 2020.06.08.20125484.
- 565 38. Dashti, H., et al., *SARS2 simplified scores to estimate risk of hospitalization and death*  
566 *among patients with COVID-19*. medRxiv, 2020: p. 2020.09.11.20190520.
- 567 39. Prevention, C.f.D.C.a. *Symptoms of Coronavirus*. 2020 2020].
- 568 40. Fehr, A.R. and S. Perlman, *Coronaviruses: an overview of their replication and*  
569 *pathogenesis*. Methods Mol Biol, 2015. **1282**: p. 1-23.
- 570 41. Atkinson, B. and E. Petersen, *SARS-CoV-2 shedding and infectivity*. Lancet, 2020.  
571 **395**(10233): p. 1339-1340.
- 572 42. Widders, A., A. Broom, and J. Broom, *SARS-CoV-2: The viral shedding vs infectivity*  
573 *dilemma*. Infect Dis Health, 2020. **25**(3): p. 210-215.
- 574 43. He, X., et al., *Temporal dynamics in viral shedding and transmissibility of COVID-19*.  
575 Nat Med, 2020. **26**(5): p. 672-675.


- 576 44. Wolfel, R., et al., *Virological assessment of hospitalized patients with COVID-2019*.  
577 Nature, 2020. **581**(7809): p. 465-469.
- 578 45. Argyropoulos, K.V., et al., *Association of Initial Viral Load in Severe Acute Respiratory*  
579 *Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms*. Am J  
580 Pathol, 2020. **190**(9): p. 1881-1887.
- 581 46. Chen, D., et al., *Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report*.  
582 Int J Infect Dis, 2020. **93**: p. 297-299.
- 583 47. Chen, Y., et al., *Re-evaluation of retested nucleic acid-positive cases in recovered*  
584 *COVID-19 patients: Report from a designated transfer hospital in Chongqing, China*. J  
585 Infect Public Health, 2020. **13**(7): p. 932-934.
- 586 48. He, F., et al., *Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-*  
587 *19 patient with systemic lupus erythematosus: a case report and review*. Clin Rheumatol,  
588 2020.
- 589 49. Batisse, D., et al., *Clinical recurrences of COVID-19 symptoms after recovery: viral*  
590 *relapse, reinfection or inflammatory rebound?* J Infect, 2020.
- 591 50. Victor Okhuese, A., *Estimation of the Probability of Reinfection With COVID-19 by the*  
592 *Susceptible-Exposed-Infectious-Removed-Undetectable-Susceptible Model*. JMIR Public  
593 Health Surveill, 2020. **6**(2): p. e19097.
- 594 51. Alizargar, J., *Risk of reactivation or reinfection of novel coronavirus (COVID-19)*. J  
595 Formos Med Assoc, 2020. **119**(6): p. 1123.
- 596 52. Roy, S., *COVID-19 Reinfection: Myth or Truth?* SN Compr Clin Med, 2020(May 29): p.  
597 1-4.  
598

# Figure 1.


## A







## B



## C




# Figure 2.


**A****B****C****D**

# Figure 3.


## A




## B




## C




## D




## E



## F



# Figure 4.




# Figure 5.

SARS-CoV-2 Wuhan-Hu-1

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.08.20125989>; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

- Facility B
- Facility C
- Facility D
- Facility E
- Reference Genomes



SARS-CoV-2 CO-CDC-5607/2020

SARS-CoV-2 USA-CA1/2020

SARS-CoV-2 WA1-F6/2020






SARS-CoV-2 CO-CDC-5780/2020

SARS-CoV-2 CO-CDC-5610/2020

SARS-CoV-2 CO-CDC-5667/2020

5.0E-5

# Supplemental Figure 1.

**A****B****C****D****E**



# Supplemental Figure 2.

